Daily Stock Analysis, ACHV, Achieve Life Sciences Inc, priceseries

Achieve Life Sciences Inc. Daily Stock Analysis
Stock Information
Open
9.50
Close
8.93
High
9.69
Low
8.83
Previous Close
9.43
Daily Price Gain
-0.50
YTD High
18.26
YTD High Date
Jul 31, 2020
YTD Low
4.60
YTD Low Date
Mar 16, 2020
YTD Price Change
-1.47
YTD Gain
-14.12%
52 Week High
47.80
52 Week High Date
Sep 24, 2019
52 Week Low
4.60
52 Week Low Date
Mar 16, 2020
52 Week Price Change
-34.27
52 Week Gain
-79.33%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
112.20
Jan 17. 2017
130.36
9 Trading Days
16.19%
Link
LONG
Aug 29. 2017
73.80
Aug 30. 2017
78.90
1 Trading Days
6.91%
Link
LONG
Oct 26. 2017
43.60
Oct 27. 2017
46.30
1 Trading Days
6.19%
Link
LONG
Dec 7. 2017
29.20
Dec 8. 2017
31.00
1 Trading Days
6.16%
Link
LONG
Dec 22. 2017
25.40
Dec 29. 2017
26.85
4 Trading Days
5.71%
Link
LONG
Jan 29. 2019
28.40
Feb 20. 2019
32.08
15 Trading Days
12.97%
Link
LONG
Feb 21. 2019
35.80
Mar 8. 2019
48.38
11 Trading Days
35.14%
Link
LONG
Mar 14. 2019
49.00
Mar 22. 2019
57.21
6 Trading Days
16.76%
Link
LONG
Apr 22. 2019
77.20
May 9. 2019
81.81
13 Trading Days
5.97%
Link
LONG
Sep 3. 2019
39.80
Sep 12. 2019
42.81
7 Trading Days
7.57%
Link
LONG
Jul 7. 2020
8.40
Jul 8. 2020
8.90
1 Trading Days
5.95%
Link
LONG
Jul 17. 2020
8.60
Jul 23. 2020
9.15
4 Trading Days
6.40%
Link
LONG
Sep 14. 2020
8.96
Sep 21. 2020
9.46
5 Trading Days
5.61%
Link
Company Information
Stock Symbol
ACHV
Exchange
NasdaqCM
Company URL
http://www.oncogenex.com
Company Phone
425-686-1500
CEO
Scott Daniel Cormack
Headquarters
Washington
Business Address
19820 NORTH CREEK PARKWAY, SUITE 201, BOTHELL, WA 98011
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000949858
About

OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA.

Description

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. The company is headquartered in Bothell, Washington.